Filter results
You can narrow down the results using the filters
Audience
Topics
Our work
Diseases
11772 results
-
Practice Incentives Program – Quality improvement measures
This document explains quality improvement measures for general practice under the Practice Incentives Program (PIP) Quality Improvement (QI) Incentive. -
Practice Incentives Program Quality Improvement Incentive – Frequently asked questions
This document covers frequently asked questions by general practices about how the Practice Incentives Program (PIP) Quality Improvement (QI) Incentive works. -
Taskforce final report – Diagnostic Imaging Clinical Committee
This report contains the Medicare Benefits Schedule (MBS) Review Taskforce's findings and recommendations to the Australian Government on its review of Diagnostic Imaging MBS items. -
Terms of Reference for Inquiry into Earle Haven Retirement Village
Terms of reference for an independent inquiry into the events surrounding the forced relocation of residents at the Earle Haven Retirement Village. -
AISR fortnightly report no. 6 – 1 July to 14 July 2019
The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons. -
ATAGI advice on the use of Dengvaxia® for Australians
This resource provides advice for immunisation providers regarding the administration of Dengvaxia® for Australians.
-
Fifth National Aboriginal and Torres Strait Islander Bloodborne Viruses and Sexually Transmissible Infections Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Fourth National Sexually Transmissible Infections Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Fifth National Hepatitis C Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Third National Hepatitis B Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Eighth National HIV Strategy 2018–2022
This strategy is 1 of 5 national strategies that provide a framework for a high-quality and coordinated national response to bloodborne viruses (BBV) and sexually transmissible infections (STI) in Australia. -
Australian Brain Cancer Research Roadmap
This Roadmap outlines the investment strategy, rationale and implementation of the Australian Brain Cancer Mission. -
Outcomes of the Commonwealth Home Support Program (CHSP) wellness and reablement report 2018
This report shows results of a 2018 survey of Commonwealth Home Support Program (CHSP) service providers from all states and territories, except Victoria. -
Aged Care Diversity Framework action plans
This collection includes action plans to address the needs of older Aboriginal and Torres Strait Islander peoples, senior Australians from CALD backgrounds and LGBTI elders. It also includes a government action plan and a shared action plan which outlines actions to support all diverse groups. -
AISR fortnightly report no. 5 – 17 June to 30 June 2019
The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons. -
Life Saving Drugs Program – Pompe disease – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for Pompe disease. -
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for MPS II. -
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Medicines review protocol
This final protocol describes the methodology reviewers will follow to assess use of Life Saving Drugs Program medicines for paroxysmal nocturnal haemoglobinuria. -
Stillbirth research and education
Australian Government response to the Senate Select Committee on Stillbirth Research and Education Report. -
2019 PHN Childhood immunisation coverage data
The following spreadsheets provide quarterly 2019 data on childhood immunisation coverage by Primary Health Network (PHN) for all children and Aboriginal and Torres Strait Islander children. -
Quality Use of Pathology (QUP) Project Stream – Final report for the Lab Tests Online Australasia additions to support genetics, eHealth and outreach
This final report outlines the results of the Australasian Association of Clinical Biochemistry and Laboratory Medicine’s project to support genetics, eHealth and outreach. -
National Aged Care Mandatory Quality Indicator Program Manual 1.0
This version of the manual was in effect from 1 July 2019 to 30 June 2021. -
2016–17 Operations Report of the Aged Care Financing Authority (ACFA)
This is the fifth annual operations report for ACFA. It covers the period 1 July 2016 to 30 June 2017. -
2017–18 Operations Report of the Aged Care Financing Authority (ACFA)
This is the sixth annual operations report for ACFA. It covers the period 1 July 2017 to 30 June 2018. -
Sixth Report on the Funding and Financing of the Aged Care Sector – July 2018
This is the sixth annual report on funding and financing by the Aged Care Financing Authority (ACFA). It looks at the challenges facing the aged care sector in Australia and includes analysis of the data supplied by service providers in their 2016–17 financial reports.